More insights.
More insights.
Subscribe to our newsletter.
Deep dives into design thinking, creative process, and the intersection of business and aesthetics.
Evidence That Moves Markets
Nayuran’s model centers non-pharmacological therapies with daily structure, CST-style cognition sessions, movement, music, and narrative rituals. Meta-analyses show cognitive stimulation improves cognition and neuropsychiatric symptoms and can be cost-effective in maintenance formats.
In practice, this translates into calmer behavior and reduced reliance on sedating drugs—precisely what payers and families seek. A dementia RCT confirmed CST’s benefits on cognition and behavioral symptoms; broader reviews highlight non-drug approaches as first-line for agitation.
Our own operating framework tracks “Emotional ROI” (Family Peace Score, Retention Velocity, Non-Pharma Outcome Ratio). Targets include decreasing pharmacological dependency by ~25% and lifting average length of stay—key drivers of clinical and financial stability.
Clinician feedback mirrors the data.
“Since transitioning to Nayuran, my mother’s prescription load has dropped, and her mental presence improved dramatically”
notes Dr. Felix Baumann, Family Physician, Switzerland—summing up the dual win of safety and function.
As Prof. Anika Roth, Geriatric Care Researcher (Germany) observes:
“What we’re seeing at Nayuran is real-world evidence of non-pharma dementia care that works—fewer night episodes, calmer days, and lower total care costs over time.”
That is the north star for our protocols.
The Unit Economics of Belonging
Care costs in the West are accelerating. In the U.S., the annual median for a private nursing-home room is now in the ~$120k range; home-care and assisted-living costs also climbed in 2024. UK averages commonly exceed £1,500 per week for nursing care.
At the same time, EU long-term-care outlays are projected to rise materially as populations age, straining public and private payers. Cross-border solutions that deliver quality outcomes at lower unit cost become strategically attractive to insurers and families.
Thailand’s healthcare prices benefit from structural advantages. Analyses of medical services cite 30–40% (and sometimes 55–70%) savings versus the U.S./EU across many procedures—one reason the country is a top medical-travel hub. While LTC is a distinct category, the cost base advantage is clear.
Nayuran’s price architecture leverages that base. Our governance deck aligns pricing to Swiss LTC at ~€2,400/month for long-stay programs—illustrative all-in annuals near €28.8k versus ~$120k+ U.S. nursing homes and ~£80k UK nursing care, before clinical savings from lower medication use.
Investors notice the efficiency.
“In my fund’s review, Nayuran scored off the charts in operational efficiency per dollar spent. It’s a scalable platform with soul—and measurable outcomes,”
says Linda Chang, Impact VC Partner, Singapore—capturing the blend of margin discipline and mission.
A Platform Built to Scale (and to Measure)
Nayuran is more than a site—it’s a system: a licensable care protocol (the Nayuran Method™), a research and training engine (Nayuran Institute™), and a digital family layer (Family Peace System™: Memory Capsules, dashboards, remote rituals). These create outcomes and defensibility.
For partners and payers, that means repeatable quality. The Institute certifies caregivers and “Empathy Architects,” exporting skills while the Emotional Index tracks trust, mood, mobility, and medication—giving insurers and ESG funds auditable KPIs, not anecdotes.
The platform diversifies revenue—care fees, licensing, SaaS for diaspora engagement, and training—reducing cyclicality and aligning incentives around long stays, fewer crises, and family loyalty. That flywheel compounds occupancy stability and referral velocity.
Geography completes the moat. Pak Nam Pran’s dry coastal microclimate and proximity to accredited hospitals support year-round movement and low OPEX—ideal for outcome-based contracts. It’s a serene, scalable showroom for partners.
Result: a repeatable, lower-cost, higher-trust dementia-care platform that addresses Western payer pain (rising LTC inflation) with measurable, non-pharma outcomes and robust family engagement—exactly where global demand is headed.
Nayuran scored off the charts in operational efficiency per dollar spent. It’s a scalable platform with soul—and measurable outcomes that matter to families and payers.
— Linda Chang, Impact VC Partner, Singapore
Proof as a Business Model
Ageing costs are rising; traditional facilities struggle. Nayuran shows another path: clinically credible, emotionally intelligent care at a structurally lower cost base—tracked, teachable, and expandable. That’s why doctors trust it, families choose it, and investors back it.
Evidence That Moves Markets
Nayuran’s model centers non-pharmacological therapies with daily structure, CST-style cognition sessions, movement, music, and narrative rituals. Meta-analyses show cognitive stimulation improves cognition and neuropsychiatric symptoms and can be cost-effective in maintenance formats.
In practice, this translates into calmer behavior and reduced reliance on sedating drugs—precisely what payers and families seek. A dementia RCT confirmed CST’s benefits on cognition and behavioral symptoms; broader reviews highlight non-drug approaches as first-line for agitation.
Our own operating framework tracks “Emotional ROI” (Family Peace Score, Retention Velocity, Non-Pharma Outcome Ratio). Targets include decreasing pharmacological dependency by ~25% and lifting average length of stay—key drivers of clinical and financial stability.
Clinician feedback mirrors the data.
“Since transitioning to Nayuran, my mother’s prescription load has dropped, and her mental presence improved dramatically”
notes Dr. Felix Baumann, Family Physician, Switzerland—summing up the dual win of safety and function.
As Prof. Anika Roth, Geriatric Care Researcher (Germany) observes:
“What we’re seeing at Nayuran is real-world evidence of non-pharma dementia care that works—fewer night episodes, calmer days, and lower total care costs over time.”
That is the north star for our protocols.
The Unit Economics of Belonging
Care costs in the West are accelerating. In the U.S., the annual median for a private nursing-home room is now in the ~$120k range; home-care and assisted-living costs also climbed in 2024. UK averages commonly exceed £1,500 per week for nursing care.
At the same time, EU long-term-care outlays are projected to rise materially as populations age, straining public and private payers. Cross-border solutions that deliver quality outcomes at lower unit cost become strategically attractive to insurers and families.
Thailand’s healthcare prices benefit from structural advantages. Analyses of medical services cite 30–40% (and sometimes 55–70%) savings versus the U.S./EU across many procedures—one reason the country is a top medical-travel hub. While LTC is a distinct category, the cost base advantage is clear.
Nayuran’s price architecture leverages that base. Our governance deck aligns pricing to Swiss LTC at ~€2,400/month for long-stay programs—illustrative all-in annuals near €28.8k versus ~$120k+ U.S. nursing homes and ~£80k UK nursing care, before clinical savings from lower medication use.
Investors notice the efficiency.
“In my fund’s review, Nayuran scored off the charts in operational efficiency per dollar spent. It’s a scalable platform with soul—and measurable outcomes,”
says Linda Chang, Impact VC Partner, Singapore—capturing the blend of margin discipline and mission.
A Platform Built to Scale (and to Measure)
Nayuran is more than a site—it’s a system: a licensable care protocol (the Nayuran Method™), a research and training engine (Nayuran Institute™), and a digital family layer (Family Peace System™: Memory Capsules, dashboards, remote rituals). These create outcomes and defensibility.
For partners and payers, that means repeatable quality. The Institute certifies caregivers and “Empathy Architects,” exporting skills while the Emotional Index tracks trust, mood, mobility, and medication—giving insurers and ESG funds auditable KPIs, not anecdotes.
The platform diversifies revenue—care fees, licensing, SaaS for diaspora engagement, and training—reducing cyclicality and aligning incentives around long stays, fewer crises, and family loyalty. That flywheel compounds occupancy stability and referral velocity.
Geography completes the moat. Pak Nam Pran’s dry coastal microclimate and proximity to accredited hospitals support year-round movement and low OPEX—ideal for outcome-based contracts. It’s a serene, scalable showroom for partners.
Result: a repeatable, lower-cost, higher-trust dementia-care platform that addresses Western payer pain (rising LTC inflation) with measurable, non-pharma outcomes and robust family engagement—exactly where global demand is headed.
Nayuran scored off the charts in operational efficiency per dollar spent. It’s a scalable platform with soul—and measurable outcomes that matter to families and payers.
— Linda Chang, Impact VC Partner, Singapore
Proof as a Business Model
Ageing costs are rising; traditional facilities struggle. Nayuran shows another path: clinically credible, emotionally intelligent care at a structurally lower cost base—tracked, teachable, and expandable. That’s why doctors trust it, families choose it, and investors back it.
Evidence That Moves Markets
Nayuran’s model centers non-pharmacological therapies with daily structure, CST-style cognition sessions, movement, music, and narrative rituals. Meta-analyses show cognitive stimulation improves cognition and neuropsychiatric symptoms and can be cost-effective in maintenance formats.
In practice, this translates into calmer behavior and reduced reliance on sedating drugs—precisely what payers and families seek. A dementia RCT confirmed CST’s benefits on cognition and behavioral symptoms; broader reviews highlight non-drug approaches as first-line for agitation.
Our own operating framework tracks “Emotional ROI” (Family Peace Score, Retention Velocity, Non-Pharma Outcome Ratio). Targets include decreasing pharmacological dependency by ~25% and lifting average length of stay—key drivers of clinical and financial stability.
Clinician feedback mirrors the data.
“Since transitioning to Nayuran, my mother’s prescription load has dropped, and her mental presence improved dramatically”
notes Dr. Felix Baumann, Family Physician, Switzerland—summing up the dual win of safety and function.
As Prof. Anika Roth, Geriatric Care Researcher (Germany) observes:
“What we’re seeing at Nayuran is real-world evidence of non-pharma dementia care that works—fewer night episodes, calmer days, and lower total care costs over time.”
That is the north star for our protocols.
The Unit Economics of Belonging
Care costs in the West are accelerating. In the U.S., the annual median for a private nursing-home room is now in the ~$120k range; home-care and assisted-living costs also climbed in 2024. UK averages commonly exceed £1,500 per week for nursing care.
At the same time, EU long-term-care outlays are projected to rise materially as populations age, straining public and private payers. Cross-border solutions that deliver quality outcomes at lower unit cost become strategically attractive to insurers and families.
Thailand’s healthcare prices benefit from structural advantages. Analyses of medical services cite 30–40% (and sometimes 55–70%) savings versus the U.S./EU across many procedures—one reason the country is a top medical-travel hub. While LTC is a distinct category, the cost base advantage is clear.
Nayuran’s price architecture leverages that base. Our governance deck aligns pricing to Swiss LTC at ~€2,400/month for long-stay programs—illustrative all-in annuals near €28.8k versus ~$120k+ U.S. nursing homes and ~£80k UK nursing care, before clinical savings from lower medication use.
Investors notice the efficiency.
“In my fund’s review, Nayuran scored off the charts in operational efficiency per dollar spent. It’s a scalable platform with soul—and measurable outcomes,”
says Linda Chang, Impact VC Partner, Singapore—capturing the blend of margin discipline and mission.
A Platform Built to Scale (and to Measure)
Nayuran is more than a site—it’s a system: a licensable care protocol (the Nayuran Method™), a research and training engine (Nayuran Institute™), and a digital family layer (Family Peace System™: Memory Capsules, dashboards, remote rituals). These create outcomes and defensibility.
For partners and payers, that means repeatable quality. The Institute certifies caregivers and “Empathy Architects,” exporting skills while the Emotional Index tracks trust, mood, mobility, and medication—giving insurers and ESG funds auditable KPIs, not anecdotes.
The platform diversifies revenue—care fees, licensing, SaaS for diaspora engagement, and training—reducing cyclicality and aligning incentives around long stays, fewer crises, and family loyalty. That flywheel compounds occupancy stability and referral velocity.
Geography completes the moat. Pak Nam Pran’s dry coastal microclimate and proximity to accredited hospitals support year-round movement and low OPEX—ideal for outcome-based contracts. It’s a serene, scalable showroom for partners.
Result: a repeatable, lower-cost, higher-trust dementia-care platform that addresses Western payer pain (rising LTC inflation) with measurable, non-pharma outcomes and robust family engagement—exactly where global demand is headed.
Nayuran scored off the charts in operational efficiency per dollar spent. It’s a scalable platform with soul—and measurable outcomes that matter to families and payers.
— Linda Chang, Impact VC Partner, Singapore
Proof as a Business Model
Ageing costs are rising; traditional facilities struggle. Nayuran shows another path: clinically credible, emotionally intelligent care at a structurally lower cost base—tracked, teachable, and expandable. That’s why doctors trust it, families choose it, and investors back it.